Core Insights - Tempus AI, Inc. reported a narrower adjusted loss of 11 cents per share for Q3 2025, outperforming the Zacks Consensus Estimate by 31.3% [1] - The company experienced a significant revenue increase of 84.7% year-over-year, totaling $334.2 million, which also exceeded the Zacks Consensus Estimate by 2.4% [2] Revenue Breakdown - Genomics revenues reached $252.9 million, marking a 117.2% increase year-over-year, with oncology testing contributing $139.5 million (up 31.7%) and hereditary testing contributing $102.6 million (up 32.8%) [3] - The Data and Services product line generated $81.3 million in sales, reflecting a 26.1% year-over-year growth, driven by a 37.6% increase in data licensing [4] Margin Performance - Gross profit for Q3 was $209.9 million, up 98.4% from the previous year, with an adjusted gross margin of 62.8%, an increase of 432 basis points [5] - Total adjusted operating expenses rose to $232.8 million, an 80.8% increase year-over-year, resulting in an operating loss of $22.9 million, unchanged from the previous year [5] Liquidity Position - As of the end of Q3 2025, the company had cash and cash equivalents of $655.9 million, a significant increase from $186.3 million at the end of Q2 [6] - Cumulative net cash used in investing activities was $387.6 million, compared to $122.4 million a year ago [6] Full-Year Outlook - Tempus raised its 2025 revenue guidance to approximately $1.265 billion, indicating nearly 80% annual growth, slightly below the Zacks Consensus Estimate of $1.26 billion [7] - Adjusted EBITDA for the year is now expected to be $20 million, up from the previous estimate of $5 million [9] Strategic Developments - The company achieved several milestones in Q3, including the acquisition of Paige, an AI company in digital pathology, and obtaining FDA clearance for multiple diagnostic devices [10] - Despite the operating loss, the raised revenue guidance is seen as a positive indicator for the stock [10]

Core Insights - Tempus AI reported a revenue of $334.21 million for the quarter ended September 2025, reflecting an 84.7% increase year-over-year and a 2.38% surprise over the Zacks Consensus Estimate of $326.43 million [1] - The company's EPS was -$0.11, an improvement from -$0.25 in the same quarter last year, with a surprise of +31.25% compared to the consensus estimate of -$0.16 [1] Revenue Breakdown - Net Revenue from Data and Services was $81.33 million, slightly below the average estimate of $81.6 million from five analysts [4] - Net Revenue from Genomics reached $252.88 million, exceeding the average estimate of $244.82 million from five analysts [4] Profitability Metrics - Non-GAAP Gross Profit from Genomics was reported at $155.9 million, surpassing the estimated $141.1 million from three analysts [4] - Non-GAAP Gross Profit from Data and Services was $56.66 million, falling short of the estimated $60.07 million from three analysts [4] Stock Performance - Over the past month, Tempus shares have returned -4.7%, contrasting with the Zacks S&P 500 composite's +2.1% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Financial Performance - Tempus AI reported a net loss of $42.8 million in Q2 2025, significantly improved from a net loss of $552.2 million in the same quarter last year [1][8] - Total revenues increased by 89.6% year over year to $314.6 million, driven by a 115% surge in genomics revenues to $241.8 million and a 35.7% increase in Data and Services revenues to $73 million [2][8] - Gross profit rose sharply to $195 million, reflecting a 160% year-over-year increase, attributed to improved cost management and a focus on higher-margin products [3][8] Operational Efficiency - Adjusted EBITDA improved from a negative $16 million in Q1 2025 to a negative $5.6 million in Q2 2025, indicating stronger cost discipline and operational leverage [3] - The company ended the quarter with $293 million in cash and marketable securities, an increase of approximately $70 million from the previous quarter [4] Market Position - Tempus AI's stock has outperformed the industry, with a 41.3% increase over the past year compared to the industry's 17% growth and the S&P 500's 17.4% improvement [7] - The company's current forward Price-to-Sales (P/S) ratio stands at 9.28X, higher than the industry average of 5.83X, indicating a potentially expensive valuation [9] Peer Comparisons - Guardant Health reported a net loss of $99.9 million for Q2 2025, an improvement driven by 31% year-over-year top-line growth and significant gross margin expansion [5] - Exact Sciences reported a net loss of $1.19 million, an improvement of $14.6 million from the previous year, supported by a 16% growth in total revenue and a quarterly gross profit increase of 15.2% [6]

Core Insights - Tempus AI's stock has increased nearly 13% since the release of its second-quarter 2025 earnings, driven by strong revenue growth and strategic positioning in a high-value market [1] - The company reported an 89.6% year-over-year revenue increase, primarily due to a significant rise in Genomics revenues and growth in its Data and Services segment [1][6] - Gross profit more than doubled, and adjusted EBITDA losses narrowed, indicating a clear path to profitability [2][6] Financial Performance - Revenues rose 89.6% year over year, surpassing the Zacks Consensus Estimate by 5.12%, with Genomics revenues surging by 115% and Data and Services increasing by 35.7% [6][9] - Adjusted operating expenses decreased by 57.8%, leading to a reduction in adjusted EBITDA losses to $5.6 million from $31.2 million a year ago [7][9] - The company has raised its full-year revenue guidance and strengthened liquidity through a $750 million convertible note offering [2][8] Market Position - In August, Tempus AI's shares surged 17.3%, outperforming the Medical Info Systems industry, which declined by 3% [3] - The stock is trading above its 50-day and 200-day moving averages, indicating upward momentum and price stability [10] - Despite strong performance, the stock is currently overvalued compared to its industry, with a forward price-to-sales ratio of 7.98, higher than the industry average of 5.57 [12] Future Outlook - Tempus AI is positioned to achieve sustainable profitability soon, supported by high-margin revenue growth and disciplined cost control [8][13] - Management has reaffirmed its $5 million adjusted EBITDA target for 2025, representing a $110 million improvement over 2024 [7] - The company's ability to maintain growth momentum and control costs will be crucial for its path to sustained profitability [13]

Core Insights - Tempus AI reported $193.8 million in Genomics revenues for Q1 2025, marking an increase of nearly 89% year over year, driven by a 20% growth in oncology test volumes and higher average revenue per test due to increased Medicare reimbursement rates [1][8] - The company is set to launch a new liquid biopsy assay, xM for treatment response monitoring, which will track changes in tumor fraction during immune-checkpoint inhibitor therapies, potentially influencing treatment decisions [2] - Tempus is also preparing to launch its first whole-genome sequencing test, Xh, aimed at detecting clinically relevant variants in hematological oncology by next year [3] - A companion diagnostic test is being developed in collaboration with Verastem Oncology, leveraging Tempus' FDA-approved xT CDx assay in clinical trials for ovarian cancer treatment [4] Industry Updates - Guardant Health reported a 20% year-over-year growth in oncology revenues, with a 25% increase in test volumes, and launched a hereditary cancer test [5] - Exact Sciences is experiencing strong international adoption of its Oncotype DX genomic test and has launched Cologuard Plus, which is expected to reduce false positives significantly [6] Financial Performance - Tempus AI shares have increased by 105.3% year to date, outperforming the industry average growth of 28% [7] - The company is trading at a forward Price-to-Sales ratio of 8.60X, compared to the industry average of 6.02X [9] - The Zacks Consensus Estimate for Tempus AI's 2025 earnings has been trending upward over the past 90 days, indicating positive market sentiment [11]

Core Insights - Tempus AI (TEM) is on track to achieve a significant milestone in its 10th year, projecting a full-year adjusted EBITDA of $5 million, which represents an improvement of approximately $110 million over 2024 [1] - The company narrowed its adjusted EBITDA loss by $27.8 million year over year to negative $16.2 million, indicating effective cost management [1][10] Revenue and Profitability - First-quarter revenues surged by 75.4% year over year, driven by an 89% increase in Genomics, a 31% rise in Oncology testing, and a $63.5 million contribution from Hereditary testing [2] - Gross profit increased at an even higher rate of 99.8% year over year, nearly doubling the growth rate from the previous quarter, supported by gross margin expansion in Genomics and Data and services [2] Competitive Landscape - Compared to older peers like Guardant Health and Myriad Genetics, which are still facing significant annual losses, Tempus is experiencing rapid growth and margin improvements, positioning itself for a promising shift to profitability [3] - Guardant Health reported an adjusted EBITDA loss of $58.5 million for Q1 2025, while Myriad Genetics posted an adjusted EBITDA near breakeven [4][5] Stock Performance - Year to date, Tempus AI shares have increased by 71.8%, significantly outperforming the industry average growth of 22.9% [8][10] - The stock trades at a forward 12-month sales multiple of 7.36X, which is lower than its median of 28.64X but above the industry average of 6.03X [9]

As filed with the Securities and Exchange Commission on June 13, 2024 Registration No. 333-279558 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER Table of Contents THE SECURITIES ACT OF 1933 Tempus AI, Inc. (Exact name of Registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 7370 47-4903308 (Primary Standard Industrial Classification Code Number) 600 West Chicago Avenue, ...

Table of Contents As filed with the Securities and Exchange Commission on May 20, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Tempus AI, Inc. (Exact name of Registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 7370 47-4903308 (Primary Standard Industrial Classification Code Number) 600 West Chicago Avenue, Suite 510 Chicago, Illino ...